| Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. | |
| | |
MedLine Citation:
|
PMID: 20563998 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Introduction: We sought to examine the impact of ergocalciferol (ERGO) on recombinant human erythropoietin (EPO) use in a cohort of 25-OH vitamin D (25-D)-deficient hemodialysis (HD) patients. Methods: Baseline 25-D levels were obtained for all patients who received HD >6 months in our unit. Patients with levels between 10 and 30 ng/mL received ERGO 50,000 IU x 4 doses and patients with levels <10 ng/mL received 50,000 IU x 6 doses over a 4-month period. Monthly dose of EPO was recorded at baseline and after ERGO supplementation. Results: Baseline 25-D levels were <30 ng/mL in 89% of tested patients. Eighty-one patients were included in this study. Mean baseline 25-D level was 15.3 ± 7.1 ng/mL and increased to 28.5 ± 8.6 ng/mL after ERGO (p<0.0001), and median baseline EPO dose was 21,933 U/month (interquartile range [IQR] 13,867-35,967) and decreased to 18,400 U/month (IQR 11,050-33,000) after ERGO (p=0.17). Forty-six patients (57%) required less EPO after ERGO compared with baseline: 15,450 U/month (IQR 10,056-23,575) vs. 26,242 U/month (IQR 15,717-40,167), respectively (p<0.0001). Thirty-five patients (43%) required a higher dose of EPO after ERGO, 26,350 U/month (IQR 15,875-46,075) vs. 17,667 U/month (IQR 12,021-23,392), respectively (p=0.016). Mean age, sex, vintage, diabetes status, race and 25-D levels did not differ in these 2 groups of patients, either at baseline or after ERGO. Monthly hemoglobin, iron saturation, albumin, intact parathyroid hormone, calcium and phosphorus were unchanged after ERGO in these 2 groups. Conclusions: ERGO use in 25-D-deficient HD patients may lessen the need for EPO. We recommend more aggressive supplementation with ERGO in future studies to achieve levels >30 ng/mL. |
| | |
Authors:
|
Victoria A Kumar; Dean A Kujubu; John J Sim; Scott A Rasgon; Philip S Yang |
Related Documents
:
|
16326738 - Evidence against a contribution of conventional urine risk factors to de novo esrd rena... 16362158 - Imbalance between production and scavenging of hydroxyl radicals in patients maintained... 17993768 - Srankl/osteoprotegerin complex and biochemical markers in a cohort of male and female h... 10800748 - Effects of chronic neuroleptic administration on the hypothalamo-pituitary-gonadal axis... 21089008 - Performance of estimated glomerular filtration rate prediction equations in preeclampti... 18760708 - The expanding role of arsenic in acute promyelocytic leukemia. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of nephrology Volume: 24 ISSN: 1121-8428 ISO Abbreviation: J. Nephrol. Publication Date: 2011 Jan-Feb |
Date Detail:
|
Created Date: 2010-12-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9012268 Medline TA: J Nephrol Country: Italy |
Other Details:
|
Languages: eng Pagination: 98-105 Citation Subset: IM |
Affiliation:
|
Southern California Permanente Medical Group, Los Angeles Medical Center, Los Angeles, California - USA, and Department of Internal Medicine, University of California, Los Angeles, California - USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High-frequency ultrasound biomicroscopy of the anterior segment morphometry before and immediately a...
Next Document: CT angiography versus conventional digital angiography in preoperative assessment for Chinese living...